- Home
- GPRO vs EXEL Comparison
GPRO vs EXEL Comparison
Compare GPRO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- EXEL
- Stock Information
- Founded
- GPRO 2004
- EXEL 1994
- Country
- GPRO United States
- EXEL United States
- Employees
- GPRO N/A
- EXEL 1147
- Industry
- GPRO Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPRO Consumer Discretionary
- EXEL Health Care
- Exchange
- GPRO Nasdaq
- EXEL Nasdaq
- Market Cap
- GPRO N/A
- EXEL 9.8B
- IPO Year
- GPRO 2014
- EXEL 2000
- Fundamental
- Price
- GPRO $0.62
- EXEL $37.43
- Analyst Decision
- GPRO Hold
- EXEL Buy
- Analyst Count
- GPRO 1
- EXEL 18
- Target Price
- GPRO $1.50
- EXEL $37.59
- AVG Volume (30 Days)
- GPRO 4.8M
- EXEL 2.4M
- Earning Date
- GPRO 05-12-2025
- EXEL 05-02-2025
- Dividend Yield
- GPRO N/A
- EXEL N/A
- EPS Growth
- GPRO N/A
- EXEL 170.77
- EPS
- GPRO N/A
- EXEL 1.76
- Revenue
- GPRO $801,473,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- GPRO N/A
- EXEL $5.82
- Revenue Next Year
- GPRO $5.05
- EXEL $10.81
- P/E Ratio
- GPRO N/A
- EXEL $21.27
- Revenue Growth
- GPRO N/A
- EXEL 18.50
- 52 Week Low
- GPRO $0.40
- EXEL $20.14
- 52 Week High
- GPRO $1.98
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- GPRO 57.09
- EXEL 57.87
- Support Level
- GPRO $0.48
- EXEL $35.34
- Resistance Level
- GPRO $0.55
- EXEL $37.67
- Average True Range (ATR)
- GPRO 0.05
- EXEL 1.32
- MACD
- GPRO 0.02
- EXEL 0.22
- Stochastic Oscillator
- GPRO 92.98
- EXEL 95.46
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.